Silexion Therapeutics SLXN

Silexion Therapeutics Corp is a clinical stage oncology focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the KRAS gene. The company focuses on silencing the KRAS oncogene itself using chemically modified small interfering RNA to prevent production of the pathogenic protein. Its lead product candidate SIL204 is a second generation siRNA designed to target KRAS G12D and KRAS G12V mutations in patients with locally advanced pancreatic cancer.

As a pre revenue company Silexion Therapeutics Corp does not currently generate product sales. The firm expects to generate future revenue from the commercialization of its therapeutic candidates pending regulatory approval and successful clinical trials.

Silexion Therapeutics Corp occupies a niche in the oncology market by targeting the KRAS gene upstream of protein formation unlike small molecule inhibitors that act on the KRAS protein after it is produced. Key competitors include Amgen and Bristol Myers Squibb which have approved KRAS G12C inhibitors for non small cell lung cancer and several early stage companies pursuing pan KRAS strategies such as Revolution Medicines Erasca and Jacobio AstraZeneca. The company’s differentiated mechanism of RNA interference offers a potential advantage in tumors where current inhibitors have limited activity and may reduce resistance mechanisms.

Silexion Therapeutics Corp intends to serve patients with KRAS driven solid tumors initially focusing on those with locally advanced pancreatic cancer. The company’s customers will be hospitals oncology clinics and treatment centers that administer chemotherapy and advanced therapies to cancer patients.